Rabo Ventures invests in medical Artificial Intelligence start-up Aidence

  • The Series A financing round of 10 million euro was led by Inkef Capital and Rabo Ventures
  • Aidence supports medical professionals with medical diagnostics based medical image analysis
  • This investment brings the total financing raised by Aidence to over 12.5 million euro

Rabo Ventures, an investment initiative by Rabobank has invested in Artificial Intelligence (AI) start-up Aidence. This Amsterdam based company aims to improve medical diagnostics by applying Deep Learning to medical image analysis. Rabo Ventures participated in this 10 million euro series A investment round led by Inkef Capital.

Other exisiting investors in Aidence include Northzone, HenQ en Health Innovation. This investment brings Aidence’s total funding to 12.5 million euro.

“Mathijs Koens from Rabo Ventures: “With its practical AI solution for radiologists, Aidence fits very well with our ambition to contribute to improving the healthcare ecosystem and ultimately retaining affordable healthcare for all.”

About Rabo Ventures

Rabo Ventures is part of Rabo Corporate Investments, the captive investment arm of Rabobank (previously Rabo Private Equity). Rabo Ventures invests in a wide range of innovative start-ups in healthcare, sustainability, smart industries and food & agri. Koens: “From Rabo Ventures, we are dedicated to fulfilling a supporting role and building value by leveraging Rabobank’s network, knowledge and position for the benefit of the companies we invest in.”

Rabo Ventures has a different focus than Rabo Frontier Ventures, the strategic investment fund of Rabobank aimed at Fintech and Food & Agri companies.

About Aidence

Aidence was founded in Amsterdam in 2015 by Mark-Jan Harte (CEO) and Jeroen van Duffelen (COO). Since then, the company has made waves in the medical imaging industry with its AI solution, Veye Chest. Lung cancer is one of the most common cancers worldwide and early detection is of great importance for survival. Aidence's AI-enabled pulmonary nodule management assistant, Veye Chest, connects with existing imaging infrastructure and enables radiologists to better spot and track changes in pulmonary nodules. Veye Chest is already installed in more than 10 hospitals in the Netherlands, United Kingdom and Scandinavia and processes hundreds of studies per week.

CEO Mark-Jan Harte says: “We’ve been determined since day one to deliver a tangible clinical AI solution that can be used by healthcare professionals to help their patients. We welcome INKEF and Rabo Ventures on our journey as we strive to shape the future of the medical imaging industry. With this funding we will continue building our European market expansion while also building towards FDA clearance giving us access to the US healthcare market. This investment will allow our research and development team to expand and explore new avenues for the Veye platform to support our radiologist AI pioneers and the patients they care for.”

Published: 20 February 2019, 12:00 CET

Contact

Telephone
+ 31 (0) 30 216 2758

Email
pressoffice@rabobank.nl

More contact information